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Abstract
Gestational diabetes mellitus reflects impaired maternal insulin secretion relative to demand prior to pregnancy, as well
as temporary metabolic stressors imposed by the placenta and fetus. Thus, after delivery, women with gestational
diabetes have increased risk of diabetes and recurrent gestational diabetes because of their underlying impairment, which
may be further exacerbated by fat accretion during pregnancy and post-partum deterioration in lifestyle behaviours. This
hypothetical model is discussed in greater detail, particularly the uncertainty regarding pregnancy as an accelerator of
b-cell decline and the role of gestational weight gain. This report also presents risk estimates for future glucose
intolerance and diabetes and reviews modifiable risk factors, particularly body mass and lifestyle alterations, including
weight loss and breastfeeding. Non-modifiable risk factors such as race/ethnicity and insulin use during pregnancy are
also discussed. The review concludes with current literature on lifestyle modification, recommendations for post-partum
glucose screening, and future directions for research to prevent maternal disease.
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Introduction
Women with histories of gestational diabetes mellitus are at
increased risk for several glucose intolerant states following
delivery, including gestational diabetes in future pregnancies
and diabetes mellitus. In this article, I describe briefly a
hypothetical model of pregnancy as a maternal stressor and
follow with a review of risk and risk factors for gestational
diabetes recurrence and post-partum maternal diabetes. I
conclude with a discussion of how varying diagnostic
guidelines for gestational diabetes affect estimates of
post-partum risk and current recommendations for post-
partum diabetes screening.
Hypothetical model of pregnancy as a
metabolic stressor
Gestational diabetes has classically been defined as any
glucose intolerance identified during pregnancy [1]. How-
ever, it has long been recognized that the diagnosis includes
both (1) women who have diabetes preceding pregnancy and
were not detected because of lack of screening for diabetes,
as well as (2) women who had normal glucose levels prior to
pregnancy, but had deterioration of glucose levels during
pregnancy. Recent recommendations for gestational diabetes
screening strategies attempt to distinguish between overt
diabetes vs. gestational diabetes during pregnancy, i.e.
glucose elevations that precede pregnancy vs. glucose eleva-
tions that occur during pregnancy [2]. While these screening
strategies have not been universally adopted, the prevailing
paradigm of gestational diabetes remains that of a disease
state characterized by underlying defects in maternal insulin
sensitivity and secretion, which are unmasked in response to
the metabolic stressors of pregnancy [3]. These metabolic
adaptations are informed by placental and fetal hormone
production, which may vary between pregnancies [4,5].
Post-partum glucose tolerance is the end result of several
factors (Fig. 1): maternal insulin sensitivity and secretion
prior to pregnancy, intra-partum stresses upon b-cell func-
tion, intra-partum accretion of energy stores that persist
after delivery, and post-partum behaviours. The contribu-
tion of each of these factors is determined by the degree to
which temporary stresses such as placental and fetal
hormone production affected glucose levels during preg-
nancy. It is likely that, for women with less b-cell reserve
prior to pregnancy, the contribution of fetal and placental
factors and pregnancy-related fat accretion is smaller than
for women with greater reserve prior to pregnancy.Correspondence to: Catherine Kim. E-mail: cathkim@umich.edu
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Conversely, pregnancy-related fat accretion and post-partum
behaviours will have a greater influence upon post-partum
glucose tolerance among women with greater pre-conception
b-cell reserve.
Maternal metabolic adaptations, particularly in the second
half of pregnancy, direct glucose and amino acids to the
growing fetus. During a healthy pregnancy, increases in
placental hormones, including prolactin and human placen-
tal lactogen (also known as chorionic somatomammotropin),
among other hormones [6], lead to an increase in the number
of pancreatic b-cells [7] and subsequent increases in insulin
secretion. These increases in insulin secretion are accompa-
nied by declines in maternal insulin sensitivity in the second
half of pregnancy [8]. These declines in insulin sensitivity are
concurrent with increases in other placental hormones,
including human placental lactogen, progesterone and
growth hormone [4], as well as adipokines such as leptin
and tumour necrosis factor-alpha [5]. Compared with
women with healthy pregnancies, women with gestational
diabetes have relatively reduced levels of insulin secretion in
relation to insulin sensitivity, resulting in higher intra-partum
maternal glucose levels [9].
To what extent pregnancy depletes or ‘accelerates’ declines
in b-cell reserve is not clear. Both animal and human studies
have focused on b-cell proliferation and hypertrophy as
compared with function [6]. Data conflict [10–13] as to
whether parity is an independent risk factor for post-partum
glucose intolerance, apart from weight gained during preg-
nancy. Currently, there are no studies that include precise
measures of b-cell function, such as hyperinsulinaemic
euglycaemic glucose clamp studies, that compare insulin
secretion before and after high-risk pregnancies. Studies of
insulin secretion and sensitivity in Mexican-American
women [14] and Korean women [15] suggest that women
with gestational diabetes have a steeper decline in insulin
sensitivity and poorer b-cell compensation after delivery
compared with women without gestational diabetes. These
declines are independent of changes in weight and fat as
measured by duel-energy x-ray absorptiometry or computed
tomography scan [14]. This suggests that, once b-cell
function is impaired, the natural history is for such declines
to continue even after the stresses of pregnancy have ended.
Pregnancy-related hormone changes contribute to
increases in body weight and changes in fat distribution that
persist after pregnancy, both in healthy pregnancies as well
as gestational diabetes pregnancies [16]. In other words, the
placental and fetal factors impose stresses upon maternal
metabolism that have lasting effects upon maternal metab-
olism because of these changes in fat distribution and mass.
Fat accretion attributable to these factors occurs in addition
to the increases in gestational weight gain that have been
observed over the past decade, presumably because of
interactions between lifestyle behaviours and environmental
factors such as food quality, availability and facilitators and
barriers to physical activity [17]. The magnitude of this
‘permanent’ weight gain attributable to pregnancy is directly
related to the degree of gestational weight gain and persists
over a decade after delivery [18]. In a meta-analysis of nine
studies, women who had gestational weight gain that was
below Institute of Medicine recommendations retained 3 kg
less than women who had gestational weight gain within
recommendations at 6 months after pregnancy (95% CI –
3.72 to –2.27 kg). Women who exceeded gestational weight
gain recommendations retained 3 kg more than women
within recommendations at 3 years after pregnancy (95% CI
1.50–4.63 kg) as well as at 15 years post-partum (4.72 kg,
95% CI 2.94–6.50 kg) [18].
In summary, variations in underlying maternal insulin
secretion and sensitivity, the degree of metabolic stress posed
by factors specific to the pregnancy, including placental and
fetal hormone production and gestational weight gain, and
finally the adiposity retained from pregnancy and post-par-
tum behaviours will contribute to variations in post-partum
maternal risk for glucose intolerance and diabetes. The
following section discusses studies of the magnitude of this
risk and estimates of risk factor strength.
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FIGURE 1 Pre-conception maternal insulin sensitivity and secretion, in conjunction with placental and fetal hormone production, influence
intra-partum maternal fat accumulation as well as insulin secretion and sensitivity. Thus, post-partum glucose tolerance reflects pre-conception
metabolism altered by the adipose tissue gained during pregnancy, possibly stresses upon the pancreatic b-cell possibly accelerated by the pregnancy,
fat stores accumulated during pregnancy and retained after delivery and post-partum behaviours.
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Risk of recurrence of gestational diabetes,
post-partum diabetes and cardiovascular
disease
It is well established that women with a single gestational
diabetes pregnancy are at risk for gestational diabetes in their
future pregnancies. Among women receiving antenatal care
in one health system and who had at least two pregnancies
(n = 65 132) [19], women with gestational diabetes in their
first pregnancy had a 41% risk of gestational diabetes in their
second pregnancy, compared with 4% among women
without gestational diabetes in their first pregnancy. Among
women who had three pregnancies (n = 13 096), 57% of
women who had gestational diabetes in their first two
pregnancies also had gestational diabetes in their third
pregnancy [19]. These prevalences are similar to those
reported in another health system, which noted that, among
women with a gestational diabetes pregnancy, 38% had
gestational diabetes in a subsequent pregnancy compared
with 3.5% among women without gestational diabetes in
their first pregnancy [20].
It is also well established that women with gestational
diabetes are at increased risk for future diabetes [21] and
that, among women with diabetes, as many as one third of
women have experienced a gestational diabetes pregnancy
[22]. In a meta-analysis of 20 reports [21], women with
gestational diabetes had a sevenfold increased risk of
diabetes compared with women without gestational diabetes
(relative risk 7.43, 95% CI 4.79–11.51). It is possible that
the magnitude of risk will increase over time, as performance
of post-partum diabetes screening increases. This may affect
risk estimates for gestational diabetes recurrence. As back-
ground diabetes screening is not performed regularly, and as
women will present for antenatal care at varying gestational
ages, incidence of gestational diabetes in a future pregnancy
and pre-conception diabetes affecting a future pregnancy
exist in equilibrium. In other words, more women diagnosed
with diabetes after an index gestational diabetes pregnancy
will mean that there will be fewer women diagnosed with
recurrent gestational diabetes after an index gestational
diabetes pregnancy. Lawrence et al. noted that, between
1999 and 2005, the age- and race/ethnicity-adjusted gesta-
tional diabetes prevalence did not change significantly with
time [23]. However, among all deliveries to women with
gestational diabetes or pre-conception diabetes, the percent-
age to women with pre-conception diabetes in 1999 was
10%, which rose to 21% in 2005 [23].
Gestational diabetes is associated with increased risk of
cardiovascular dysfunction, although it is unclear whether
this occurs apart from a diagnosis of post-partum glucose
intolerance and diabetes. Compared with women with
healthy pregnancies, women with histories of gestational
diabetes have elevations in cardiovascular risk factors
including blood pressure [24–28] and unfavourable changes
in HDL and triglyceride levels [24–29]. Women with
histories of gestational diabetes had greater vascular resis-
tance, lower stroke volume, lower cardiac output [30] and
higher intimal medial thickness compared with women
without histories of gestational diabetes [31]. Small
cross-sectional studies conflict as to whether flow-mediated
dilation is impaired among women with histories of gesta-
tional diabetes [32]. Carr and colleagues found that women
with a history of gestational diabetes were more likely to
experience more cardiovascular events and at earlier ages
than women without a history of gestational diabetes [33].
However, gestational diabetes screening was not universal in
the cohort as women with histories of gestational diabetes
conceived approximately in the 1970s, and it is possible that
recall bias or selective screening affected risk estimates.
Moreover, the cohort examined had two affected family
members with diabetes and therefore was at particularly high
risk for diabetes. Other reports note that gestational diabetes
is associated with increased risk of cardiovascular events and
hospitalizations, although diabetes was not adjusted for in
one report [34] and the association between gestational
diabetes and cardiovascular event risk was attenuated by
adjusting for diabetes in the other report [35].
Modifiable risk factors for future risk of
glucose intolerance: body mass
In the aforementioned studies of gestational diabetes recur-
rence, recurrence was high, but not universal. Approximately
two-thirds to half of women with a second pregnancy do not
have gestational diabetes in the second pregnancy [36,37].
Thus, among the majority of women with gestational
diabetes who also have a second pregnancy, gestational
diabetes does not recur, despite increases in maternal age and
presumed age-related declines in b-cell function. While it is
unknown to what extent recurrence reflects pregnancy-spe-
cific placental and fetal factors vs. interval changes in
maternal insulin secretion relative to action, there may be a
role for risk factor modification prior to the second
pregnancy or during the second pregnancy.
The risk factor thought to explain the greatest variance in
risk, and which also is the most amenable to modification, is
maternal weight before the subsequent pregnancy. While
weight gain between pregnancies and at the subsequent
pregnancy were inconsistently associated with gestational
diabetes risk in older reports [38], more recent reports suggest
that maternal weight gain in between pregnancies might play
a larger role in gestational diabetes recurrence, perhaps
because of the steady increase in maternal pre-conception
BMI over the past decade [17]. In one recent examination of
22 351 women, women had a significant increase in their
odds of gestational diabetes in their subsequent pregnancy
with each unit of BMI gained between pregnancies
[20]. Specifically, women who gained 1–1.9 kg/m2 had a 1.7
increased odds of future gestational diabetes; women who
gained 2.0–2.9 kg/m2 had a 2.5 increased odds and women
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who gained over 3 kg/m2 had a 3.4 increased odds [20].While
less than 10% of women lost weight between pregnancies,
women who were overweight or obese at their index
pregnancy, but who then lost weight (approximately 2.0
kg/m2) significantly lowered their risk of future gestational
diabetes by almost 80% (odds ratio 0.26, 95% CI 0.14–
0.47). Of note, women who were not overweight at their
index gestational diabetes pregnancy, but lost weight after
their index pregnancy, did not significantly reduce their odds
of future gestational diabetes. This suggests that attributable
risk for gestational diabetes attributable to weight was low in
these women, and that weight loss may not be an ideal target
for intervention in this subpopulation [20].
As with recurrent gestational diabetes, anthropometric
factors have a strong association with future risk of diabetes.
In a systematic review conducted in 2009, body fat measures
had the most consistent associations with diabetes risk
compared with other types of factors including age, parity
and family history of diabetes [39]. Specifically, pre-preg-
nancy BMI was associated with significantly increased risk of
future diabetes after a gestational diabetes delivery; for every
1 kg increase in pre-pregnancy weight, there was a 40%
increase in odds of developing Type 2 diabetes (odds
ratio 1.40, 95% CI 1.20–1.60). Intra-partum and post-partum
weight measures were also associated with increased diabetes
risk [39]. In an examination of weight change post-partum,
Peters et al. reported that, for every 4.5-kg increase in
weight, there was a twofold increase in the risk of Type 2
diabetes, even after adjustment for other factors including
post-partum BMI, oral glucose tolerance test results and
breastfeeding [10]. In a cohort of Korean women, Cho et al.
compared the strength of association between post-partum
BMI, weight, skin thickness, waist–hip ratio and waist
circumference and diabetes risk [24]. All of the body mass
measures were associated with risk of diabetes, but waist
circumference as characterized by quartiles and body fat
measures had the strongest associations, suggesting that
adipose tissue as opposed to other tissue compartments and
visceral fat deposition as opposed other types of fat depo-
sition conferred the highest risk for diabetes.
Altering body mass through lifestyle changes including diet
and exercise has proven to be challenging among women
with histories of gestational diabetes. The most successful
intervention was among women who were overweight and
glucose intolerant and enrolled in the Diabetes Prevention
Program, a multi-centre randomized trial that concluded in
2001 [40]. Among the 350 women with histories of
gestational diabetes, intensive lifestyle change targeting 7%
reduction in enrolment weight and increased physical activity
led to significant reductions in diabetes incidence compared
with placebo [40]. The incidence of diabetes in women with
gestational diabetes randomized to lifestyle was 7.4 per 100
person-years, compared with an incidence of diabetes in the
placebo group of 15.2 per 100 person years, for a 53%
reduction in incidence.
Several Diabetes Prevention Program study characteristics
underline how difficult behaviour change in the population
with gestational diabetes can be. Women with histories of
gestational diabetes in the Diabetes Prevention Program were
approximately 43 ( 7.6) years of age and the date of their
prior gestational diabetes pregnancy specifically was not
known, although they were approximately 12 years from
their last pregnancy. Presumably, the Diabetes Prevention
Program population would be more amenable to behaviour
change than women with more recent gestational diabetes
deliveries who may face barriers to lifestyle change because of
caregiving demands imposed by young children. In addition,
women who were at extremely high risk for diabetes, and
perhaps with the greatest barriers to lifestyle change, would
have already converted to diabetes in their first decade
post-partum. However, women with gestational diabetes had
the greatest weight loss at 6 months post-randomization
(5.1 kg) and steadily increased weight thereafter, so that their
mean weight loss at 3 years was only 1.6 kg. This weight
pattern was significantly worse than in the women in the
Diabetes Prevention Program without gestational diabetes,
who had a mean weight loss at 3 years of 4.0 kg. These
weight patterns corresponded with decreases in physical
activity by the end of the study; women with gestational
diabetes had increased their activity by approximately 1.5 h
per week from baseline during the first year, but by the third
year, they reported less than 30 min of physical activity a
week [40]. As a randomized trial, the Diabetes Prevention
Program undoubtedly selected for a highly motivated group
of participants; previous Diabetes Prevention Program
reports have noted that approximately 158 000 persons
were screened and recruitment protocols emphasized a
history of gestational diabetes because of the high prevalence
of glucose intolerance among women with gestational
diabetes post-partum. However, 29 000 were excluded
because of lack of participant interest and, among partici-
pants who underwent the screening oral glucose tolerance
test, the majority were excluded because of lack of elevation
in the 2-h post-prandial value (approximately 20 000 indi-
viduals), resulting in the 3800 participants eventually ran-
domized [41]. Women with histories of gestational diabetes
randomized to metformin also had similar reductions in
incident diabetes, although it is unclear whether metformin
would have similar benefit among women with gestational
diabetes who did not have elevations in both their fasting and
2-h values at baseline, as Diabetes Prevention Program
participants had to have impaired fasting glucose as well as
significant elevations in their 2-h postprandial values.
As of yet, lifestyle interventions that successfully target
women with gestational diabetes closer to their delivery have
not been published [42]. Ferrara et al. randomized approx-
imately 100 women with gestational diabetes to a Diabetes
Prevention Program-like intervention vs. 100 women to
control and, at 1 year post-partum, women randomized to
intervention reduced their dietary fat intake [43]. Physical
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activity, breastfeeding and proportion that reached dietary
weight goals were not statistically significant between study
arms, although between-arm differences in these outcomes
were close to meeting statistical significance (P < 0.10 but
> 0.05) and women randomized to intervention were more
likely to meet their dietary fat goals than women randomized
to usual care; a larger trial is currently underway. In another
randomized controlled trial of 450 Chinese women with
histories of gestational diabetes that also advised on diet and
exercise, there were no difference in diabetes incidence
between the intervention and control group at 3 years, nor
were there differences in glucose or insulin sensitivity [44].
As in women without gestational diabetes, healthier diets
may be associated with decreased risk of diabetes among
women with histories of gestational diabetes, although such
studies are few. Among women with histories of gestational
diabetes in the Nurses’ Health Study II cohort [45], women’s
dietary patterns were scored by several scales examining
degree of adherence to the Mediterranean diet, Dietary
Approaches to Stop Hypertension (DASH) diet and the
Healthy Eating Index. Women who were the most adherent
to or in the highest quartile of the Mediterranean diet scale
had a 40% lower risk of Type 2 diabetes compared with
women in the lowest quartile (hazard ratio 0.60, 95% CI
0.44–0.82). Similar reductions in risk were observed in
women who were in the highest quartile of the DASH diet
and the Healthy Eating Index compared with the lowest
quartile. The risk reduction was partially mediated by body
mass changes. Among Korean women, greater animal fat
intake was associated with the presence of pre-diabetes and
diabetes in the early post-partum [46].
In general, women with histories of gestational diabetes
have similarly poor health behaviours compared with women
without such histories [47]. One recent report from the
Coronary Artery Risk Development in Young Adults Study
compared post-pregnancy weight and behaviours between
women with and without gestational diabetes pregnancies
[48]. Women were examined at mean of approximately
1.4 years after delivery. Women with and without gesta-
tional diabetes were similar regarding their degree of
post-partum weight retention, which averaged 3–4 kg, with
an increase in waist circumference of approximately 4 cm
compared with pre-pregnancy [48]. Women with and with-
out gestational diabetes reported similar declines in total
physical activity and increases in caloric intake, including an
increase in the percentage of calories from fat. An earlier
report from Canada noted that women with gestational
diabetes increased their leisure-time activity (although not
other types of physical activity) by 1 year after pregnancy
compared with women without such histories, indicating
there may be some variation in health behaviours by region
or service area [49]. To our knowledge, there are no
longitudinal reports of physical activity in women with
histories of gestational diabetes and reports of associated risk
reductions in future diabetes.
Modifiable behaviours: breastfeeding and
contraception choice
Breastfeeding is a behaviour that has been reported to have
favourable effects upon glucose both in the early and late
post-partum. Two reports, each examining approximately
500 women, noted that those who breastfed compared with
those who did not breastfeed had lower fasting plasma
glucose and insulin, and a lower prevalence of diabetes and
impaired glucose tolerance, at 6–9 weeks post-partum
[50,51]. Women with histories of gestational diabetes who
breastfed had a median time to diabetes of 12.3 years,
compared with 2.3 years among women who did not
breastfeed [52]. Longer periods of breastfeeding, i.e. greater
than 3 months, were associated with the lowest risks of
diabetes. This reduction in risk did not seem to be mediated
entirely through post-partum BMI, as duration of lactation
and the degree of change in post-partum BMI was not
significant [52]. Unfortunately, women with gestational
diabetes are less likely to breastfeed than women without
diabetes (odds ratio 0.75, 95% CI 0.66–0.85) after a deliv-
ery in hospital, perhaps attributable to management of these
women by specialists less focused upon breastfeeding than
other issues [53].
The lactational amenorrhoea associated with exclusive
breastfeeding may induce a relatively progestogenic state
and, combined with progestin-only contraceptive medica-
tion, may increase risk of diabetes in high-risk women.
Among Latinas with gestational diabetes, users of proges-
tin-only oral contraception and who breastfed had higher
risks of Type 2 diabetes compared with women who used
combination oestrogen–progestin contraceptives (relative
risk 2.87, 95% CI 1.57–5.27) [54]. Diabetes risk is also
increased among Latinas [29] and Navajos [55] who used
injectable progestins, in part through the weight gain
associated with injectable progestins as well as interactions
with lactation. Thus, while breastfeeding may improve
glucose, there may be interactions with contraception that
are detrimental for glucose in women in racial/ethnic groups
at high risk for glucose intolerance. While combination oral
contraception has been reported to decrease breast milk to a
greater extent than progestin-only use, study quality was
limited [56]; recent reports indicate no difference in breast-
feeding or maternal perception of breast milk production in
women randomized to contraception type [57].
Non-modifiable risk factors for future
glucose intolerance: race/ethnicity, insulin
use and glucose levels during the index
pregnancy and autoantibody status
Aside from body mass, the most consistent risk factor for
future glucose intolerance after a gestational diabetes deliv-
ery is non-white race/ethnicity. In southern California,
Getahun et al. noted that the risk of gestational diabetes
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recurrence varied by race/ethnicity, with the highest risk
reported among Asian-Pacific Islanders, who had a 45% risk
with a second pregnancy [19]. Similar risk estimates have
been reported for Koreans living in Asia [58]. It is not known
whether gestational diabetes risk might be higher in Asians
because of racial/ethnic differences in maternal insulin
secretion relative to demand prior to pregnancy or in
response to pregnancy metabolic stresses.
As with recurrent gestational diabetes, non-white race/
ethnicity may predict future diabetes risk among women
with histories of gestational diabetes [59]. This could reflect
racial/ethnic differences in underlying maternal insulin sen-
sitivity and secretion or diabetogenic effects of pregnancy.
Interestingly, within different racial/ethnic groups, gesta-
tional diabetes may confer different risks of Type 2 diabetes,
suggesting that there are racial/ethnic differences in b-cell
decline after an index gestational diabetes diagnosis. One
report examined the risk of diabetes associated with gesta-
tional diabetes within each racial/ethnic group in a cohort of
approximately 13 000 women with gestational diabetes and
65 000 women without gestational diabetes [60]. Non-His-
panic white women and Asian/Pacific Islanders had the
lowest risk for diabetes after their gestational diabetes
delivery (hazard ratio 6.5, 95% CI 5.2–8.0 and hazard
ratio 6.3, 95% CI 5.0–7.9, respectively), followed by Lati-
nas (hazard ratio 7.7, 95% CI 6.89–8.7) and African-Amer-
icans (hazard ratio 9.9, 95% CI 7.5–13.1). Similarly, in
another report from Louisiana, African-American women
with histories of gestational diabetes had a significantly
increased risk of diabetes (hazard ratio 7.43, 95% CI 6.34–
8.72) compared with non-Hispanic white women with
histories of gestational diabetes (hazard ratio 4.63, 95% CI
3.61–5.94) [59]. The finding that African-Americans have a
higher risk of diabetes after a gestational diabetes diagnosis
than non-Hispanic white women occurs with the finding that
African-Americans have generally lower or similar risk of
gestational diabetes compared with non-Hispanic white
women [61]. In other words, African-Americans decline
more rapidly after a diagnosis of gestational diabetes than
non-Hispanic white women, and this is unlikely to be due to
misclassification of GDM vs. Type 2 diabetes.
Other risk factors that have been associated with risk of
future diabetes include use of insulin as opposed to dietary
therapy during the gestational diabetes pregnancy [39]. In a
German report [52], use of insulin during pregnancy was
associated with increased risk of diabetes post-partum
regardless of maternal weight, with 90% of women who
required insulin therapy during pregnancy developing diabe-
tes by 15 years post-partum, with a median diabetes-free
survival of less than 2.5 years. These findings suggest that the
required use insulin during pregnancy reflects greater impair-
ments in b-cell function during pregnancy. Such findings are
concordant with the fact that glucose elevations on the index
glucose tolerance test during pregnancy are associated with
post-partum diabetes risk. In a 2009 review of 11 articles
[62], elevations in fasting glucose, 2-h glucose and oral
glucose tolerance test area under the curve were all associ-
ated with increased diabetes risk, although attrition exceeded
one fifth of the study population in six studies and followed
women over a relatively short period of time. Elevations in
any of the glucose values from the antenatal oral glucose
tolerance test are associated with greater post-partum
diabetes risk, but fasting glucose and 1-h glucose may be
more strongly associated with post-partum diabetes than
2- and 3-h values [22,63–72]. Women with a greater number
of abnormal tests, i.e. elevated fasting or post-challenge
values, are at greater risk for diabetes [28].
Among populations with a high-risk of Type 1 diabetes,
gestational diabetes indicates elevated risk for future Type 1
diabetes as well as Type 2 diabetes [73]. In a cohort of
Finnish women with gestational diabetes, 5% developed
Type 1 diabetes and 5% developed Type 2 diabetes within
6 years post-partum [74]. In populations with gestational
diabetes, as in non-pregnant populations, islet-cell autoanti-
body presence is a strong predictor of diabetes [74] and also
highlights the point that gestational diabetes can reflect
defects in maternal insulin secretion caused by autoimmuni-
ty, as well as b-cell exhaustion secondary to insulin
resistance. Among German women with islet-cell autoanti-
bodies and gestational diabetes, 31 of 32 women developed
diabetes, with a median diabetes-free duration post-partum
of 4.5 months (95% CI 2.5–6.5) [52]. Risk increased with
the number of antibodies present at delivery, with the risk of
Type 1 diabetes at 17% for one antibody, 61% for two
antibodies and 84% for three antibodies [13]. Similarly, in a
cohort of Swedish women with gestational diabetes [75],
autoantibodies (to glutamic acid decarboxylase 65 and
insulinoma antigen-2) were associated with greater diabetes
risk post-partum, although not with impaired glucose toler-
ance, underlining the fact that insulin resistance leading to
pre-diabetes was not a key pathway in disease progression
among these women with probable Type 1 diabetes.
Current recommendations for post-partum
screening
Recommendations for post-partum screening by medical
organizations are shown in Table 1. Data comparing the
sensitivity and specificity of these screening strategies do not
exist. In particular, it is unclear if the greater sensitivity of
the 2-h glucose is outweighed by its greater intra-individual
variation [76] and inconvenience, and the optimal frequency
of screening is also not clear. While 40% of women with
histories of gestational diabetes with glucose dysregulation
had normal fasting glucose levels [77], it is unclear if these
women would eventually be detected with a fasting glucose
or HbA1c and if they would suffer poorer perinatal
outcomes in the interim. (As the onset of other types of
maternal complications including micro- and macrovascular
disease have prolonged onset, particularly in women with
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Type 2 diabetes, it is less likely that these types of outcomes
would be averted through earlier detection of isolated
post-challenge hyperglycaemia [78].) The conservative,
albeit unvalidated, approach would be to perform a 75-g
2-h oral glucose tolerance test at the post-partum visit, in
that the 2-h value would detect additional women with
glucose intolerance; these women might have more aggres-
sive management of their diabetes at an earlier point in
time; and future pregnancy outcomes would be improved.
The women most likely to benefit would be those who had
post-challenge hyperglycaemia on their index oral glucose
tolerance test used to diagnose gestational diabetes. HbA1c
at 6 weeks post-partum may be affected by perinatal
haemoglobin shifts and, at 1-year post-partum, HbA1c did
not improve sensitivity and specificity of fasting plasma
glucose compared with a 75-g 2-h oral glucose tolerance
test at 1-year post-partum [79]. Longer-term follow-up data
are not yet available. It is also important to note that
postpartum screening is not universally performed and
may require simple reminders for both women and their
providers [80].
The International Association of Diabetes and Pregnancy
Study Groups recommendations on the diagnosis and clas-
sification of hyperglycaemia in pregnancy [2] will result in a
greater proportion of women diagnosed with gestational
diabetes compared with previous criteria that employed
higher glucose cut-offs. Conversely, more specific, but less
sensitive, gestational diabetes criteria lead to fewer women
being identified with gestational diabetes. Ferrara et al.
demonstrated this in their study, in which two sets of
diagnostic criteria for gestational diabetes were applied to
women who underwent glucose tolerance testing during
pregnancy [81]. Of these women, 3.2% had gestational
diabetes by National Diabetes Data Group criteria. Of the
same women, 4.8% had gestational diabetes by Carpenter
and Coustan criteria, which uses lower glucose cut-offs. With
the lower cut-offs, the prevalence of gestational diabetes
increased by approximately 50%. However, the additional
populations identified tended to be low risk; relative incre-
ments were greatest in low-risk age and ethnic groups,
specifically women aged < 25 years (70%) and in white
women (58%). Thus, although the denominator, women
with gestational diabetes, increased, the additional women
identified were at similar or lower risk when compared with
the original National Diabetes Data Group cohort. In
general, the lower the glucose cut-offs for the original
diagnosis of gestational diabetes, the broader the range of
risk in the population subsequently diagnosed with gesta-
tional diabetes.
Identification of a greater proportion of pregnant women
with gestational diabetes necessarily leads to a greater
denominator, and a decreased proportion subsequently
identified with post-partum glucose intolerance. Presumably,
this will lead to a lower proportion of women with
gestational diabetes at risk for post-partum diabetes or
glucose intolerance [82]. While it seems likely that post-par-
tum diabetes risk would still be elevated in this lower risk
pool, the estimates of diabetes risk could decrease. As these
new diagnostic criteria for gestational diabetes are imple-
mented, recommendations for frequency of testing and the
optimal glucose testing may be affected.
Conclusions
The gestational diabetes pregnancy provides a snapshot of
carbohydrate metabolism that reflects underlying maternal
insulin sensitivity and secretion. While we do not com-
pletely understand to what extent this snapshot will predict
post-partum alterations, we do know that women with
gestational diabetes are at significant risk for future glucose
intolerance, and the degree of this risk is associated with
both fixed and modifiable risk factors. Further investigation
into the contributions of temporary exposures from the
placenta and fetus might improve our understanding of why
not all women with gestational diabetes develop gestational
diabetes in subsequent pregnancies, and why not all women
with gestational diabetes develop future diabetes, despite
lack of improvement in body mass and lifestyle habits. The
primary therapeutic question is how to alter the natural
disease trajectory of gestational diabetes so that women
Table 1 Post-partum diabetes screening guidelines for women with histories of gestational diabetes mellitus from the National Institute for Health
and Clinical Excellence, the World Health Organization, the American Diabetes Association and the Canadian Diabetes Association (CDA)
National Institute for
Health and Clinical
Excellence (NICE) [83]
World Health
Organization
(WHO) [84]
American Diabetes
Association (ADA) [85]
Canadian Diabetes
Association (CDA) [86]
When 6 weeks post-partum 6 weeks post-partum 6–12 weeks post-partum 6 weeks post-partum
If normal, annually If normal, every 3 years If normal, 6 months
post-partum
If impaired fasting glucose or
elevated 2-h glucose, annually
Which test Fasting blood glucose Fasting blood glucose or
75-g 2-h oral glucose
tolerance test
75-g 2-h oral glucose tolerance test
(HbA1c not recommended)
75-g 2-h oral glucose
tolerance test
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avoid recurrent gestational diabetes and post-partum
diabetes. While lifestyle changes post-partum can be effec-
tive, they have proven difficult to implement in the critical
years after delivery, when women are still of childbearing
age, and when women may rapidly progress to overt
diabetes at young ages. The long-term use of medications in
this reproductive-age population is a less attractive option,
but such therapies should be tested as an adjunct approach.
In the meantime, translational research needs to be
conducted to find ways to best facilitate healthy behaviours
in this high-risk population.
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